Accurate and integrated diagnostic solutions that enable
faster and more efficient healthcare at any point of need.
miDiagnostics aims to bring clinical, blood-based diagnostics to the people who need it the most: the patients. Based around a disruptive silicon-based nanofluidic processor embedded in a low-cost test card, we are building the lab test of the future.
Cameras and chip processors built in our smartphones currently exist of billions of transistors. We apply the power of massive parallelization and miniaturization to microfluidics: many fluidic handling steps occur in parallel at a very small scale resulting in very fast turnaround times.
A key strength of semiconductor technologies is the diversity of nanofluidic processors that can be produced on a single manufacturing platform. This level of mass customization is still unprecedented in high-volume manufacturing industries. We have designed various nanofluidic processors that fit on the same platform for applications in cytology, molecular diagnostics, clinical chemistry and immunoassays, or a combination of these.
An outstanding characteristic of silicon micromachining is the precise control of features at the sub-micron level. We take advantage of this property to create disposable test cards that have the quality and accuracy of lab-based tests.
We are developing three nanoFluidic Processors to measure and quantify cells, nucleic acids, proteins and small molecules
They form the basis for a variety of test cards, addressing specific medical conditions or use cases, such as early screening and treatment of infectious diseases (eg. HPV, GBS, and HIV/HCV/HBV), rapid diagnosis of acute diseases (eg. viral versus bacterial infection, meningitis, and upper and lower respiratory tract infection), and (home) monitoring of patients (eg. HIV treatment efficacy, organ transplant CMV infection, and chemotherapy monitoring).
Contains Si chip
Analyzes a blood drop
Reads the test card
Connects via USB cable
Processing & computation
Less than 10 minutes to results
Globally Shifting Healthcare
Nicolas Vergauwe joined miDiagnostics as Chief Executive Officer in April 2018. In this capacity, Nicolas and his team will develop and extend the miDiagnostics product portfolio by building further on the groundbreaking research of Imec and Johns Hopkins University.
Until March 2018, Nicolas was Vice President Innovations at Biocartis, a molecular diagnostics company that has developed a sample-to-result platform for oncology and infectious disease applications. As VP Innovations,
Nicolas was responsible for bringing novel technologies and assay concepts to the market. Dr. Vergauwe joined Biocartis in January 2012 as a scientist after obtaining his PhD in Bioscience Engineering at the Katholieke Universiteit Leuven, Belgium in collaboration with the École Polytechnique Fédérale de Lausanne (EPFL) at Lausanne, Switzerland.
Joined miDiagnostics as Chief Financial Officer in September 2019. Alexander obtained a MSc in Business Engineering from the KULeuven and a MSc in Finance from the London School of Economics.
Alexander started his career as a strategy consultant at McKinsey&Co where he focused on M&A and private equity topics across a wide range of industries and geographies.
Alexander brings along 8 years of experience as investment manager and CFO of various companies in capex intensive industries in which he ran several divestment and acquisition, equity capital markets and debt financing processes.
Before joining miDiagnostics, Alexander was CFO of an investment holding with €300m of assets under management.
Dr. Peumans holds a Ph.D. in electrical engineering from Princeton University, and a bachelor’s and master’s degree in engineering from the Katholieke Universiteit Leuven. Prior to joining miDiagnostics, Dr. Peumans was a professor of electrical engineering at Stanford University where his work focused on large area electronics, solar energy conversion and biomedical electronics. He is the recipient of an NSF CAREER award and a Belgian-American Educational Foundation honorary fellowship.
Peter currently also leads imec’s life science technologies program. In that capacity, Dr. Peumans started the research program on silicon fluidics-based point-of-care diagnostics and helped found miDiagnostics where he is now the CTO.
Ben joined the miDiagnostics team as Director Quality and Regulatory Affairs to help lead the organization through the next stages of feasibility assessment, into design control and beyond into the marketplace.
He is responsible for the development and execution of the Regulatory and Quality Strategies for the product platform and the organization.
Ben has worked within the Pharmaceutical and Medical Device Industry for over 25 years, with companies such as Merck, Johnson & Johnson Medical, Ethicon, LifeScan, and DePuy.
During his career, Ben has had leadership positions within Project Management, Quality Assurance, Operations, Regulatory Affairs and R&D. During this time, Ben collaborated in and led a variety of product approvals, process improvements, process introductions and product launches. This has included the direction of activities across Europe, the USA and the Far East.
Ben has a BSc in Biochemistry from the University of Nottingham and a Post Graduate Diploma in Management from the University of Bradford.
Dr. Christopher Adams joined miDiagnostics in September 2019. He brings along extensive experience in translating products from early inception to product launch, particularly within the point of care diagnostics industry and within microfabricated medical diagnostics.
Before joining miDiagnostics, Christopher served for 7 years as Head of Biotechnology and Innovation at QuantuMDx. Christopher holds a PhD in Physics from the University of Glasgow.
Board of directors
Dr. Rudi Pauwels
Dr. Ir. Urbain Vandeurzen
Luc Van den hove
Dr. Stuart C. Ray, MD
miDiagnostics Raises €14m to Accelerate the Commercialization of its Disruptive, Lab-quality Silicon Chip Diagnostics Platform
Supported by existing shareholders and new investors, including tech entrepreneur Urbain Vandeurzen and life sciences entrepreneur Rudi Pauwels Technology has potential to deliver rapid test
Leuven, Belgium – January 2020 – While new solutions for health are emerging in different parts of the world, these do not always get adopted
miDiagnostics’ disposable blood testing device to be evaluated by imec for use in zero gravity environments
Leuven (BELGIUM) and Kissimmee (FLORIDA), Nov. 19 2019 – Today, imec, a world-leading research and innovation hub in nano-electronics and digital technologies announced it has
miDiagnostics has agreed a partnership with Notified Body, BSI (the Netherlands) to assess and certify the miDiagnostics Quality Systems to ISO 13485 (2016) in preparation for the CE marking and 510(k) clearance.
For miDiagnostics being a member of Leuven MindGate allows to be informed about and receive access to exclusive Leuven MindGate member activities and content.